GREY:MPHMF - Post by User
Post by
courtninjaon Feb 10, 2017 9:25am
133 Views
Post# 25827431
Upcoming Milestone Dates
Upcoming Milestone Dates C-103
- The FDA is scheduled to respond to our PIND package by March 6, 2017. Once we incorporate their recommended adjustments, we should have an approved path including particulate partners and study requirements.
- The USPTO has issued an Office Action on the patent application for the “Dual Compartment Capsule for the Administration of Orlistat”. This is a common occurrence with applications. We responded to their questions on January 26, 2017 and should have an update sometime in March, 2017. This patent is not required to commercialize C-103, but would provide an additional level of patent protection.
ToConceive
- A Strategic Brief and Brand Model presentation is scheduled for February 14, 2017.
- Online sales should launch in late April or May, 2017 with targeted sales of 2,000 units per month initially.
Female Sexual Dysfunction drug
- We anticipate hearing from the USPTO by May, 2017.
PARALT
- The USPTO patent response is expected by May, 2017